Obatoclax mesilate: Bcl-2 inhibitor apoptosis inducer oncolytic

Drugs of the Future

Volumn 32, Issue 3, 2007, Pages 228-233

  Wang, Y ^a   Serradell, N ^b   Bolos J ^b   Rosa, E ^b  

^a Prous Science ^*  (United States)

^b PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ANTINEOPLASTIC AGENT; BH 311; BH 312; BORTEZOMIB; CHLORAMBUCIL; CISPLATIN; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR BLOCKING AGENT; FLUDARABINE; GEFITINIB; GOSSYPOL; GW 2974; GX 015070; GX 15070; GX 15070 MS; INTERLEUKIN 6; MAPATUMUMAB; MELPHALAN; NPI 0052; OBATOCLAX MESILATE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN INHIBITOR; PROTEIN MCL 1; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; SOMATOMEDIN C; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; ATAXIA; CANCER CELL CULTURE; CELL STRAIN HL 60; CELL STRAIN MCF 7; CELL STRAIN U937; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DNA SYNTHESIS; DRUG ACTIVITY; DRUG BINDING; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; EUPHORIA; FOLLICULAR LYMPHOMA; HODGKIN DISEASE; HUMAN; HYPOTENSION; IN VITRO STUDY; LEUKEMIA CELL; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; LYMPHOMA; MANTLE CELL LYMPHOMA; MIXED MYELODYSPLASTIC MYELOPROLIFERATIVE DISEASE; MYELOID LEUKEMIA; MYELOMA CELL; NEUTROPENIA; PAIN; PROTEIN EXPRESSION; SIDE EFFECT; SOLID TUMOR; SOMNOLENCE; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 34250315396     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2007.032.03.1084808     Document Type: Article

References (46)

1. Attardo, G., Dairi, K., Lavallee, J.-F., Rioux, E., Tripathy, S. (Gemin X Biotechnologies, Inc.). Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases. EP 1644363, JP 2007502845, US 2005014802, WO 2004106328.
2. Reed, J.C., Pellecchia, M. Apoptosis-based therapies for hematological malignancies. Blood 2005, 108(2): 408-18.
3. Kitada, S., Pedersen, I.M., Schimmer, A., Reed, J.C. Dysregulation of apoptosis genes in hematopoietic malignancies. Oncogene 2002, 21: 3459-74.
4. Kitada, S., Reed, J.C. MCL-1 promoter insertions dial-up aggressiveness of chronic leukemia. J Natl Cancer Inst 2004, 96: 642-3.
5. Hanada, M., Delia, D., Aiello, A., Stadtmauer, E., Reed, J. Bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 1993, 82: 1820-8.
6. Reed, J. Bcl-2 family proteins: Regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol 1997, 34: 9-19.
7. Kitada, S., Leone, M., Sareth, S., Zhai, D., Reed, J.C., Pellecchia, M. Discovery, characterization and structure-activity relationships studies of pro-apoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 poteins. J Med Chem 2003, 46: 4259-64.
8. Wang, L., Liu, D., Zhang, Z.J. et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci USA 2000, 97: 7124-9.
9. Degterev, A., Lugovskoy, A., Cardone, M. et al. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat Cell Biol 2001, 3: 173-82.
10. Tzung, S., Kim, K.M., Basanez, G. et al. Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nat Cell Biol 2001, 3: 183-92.
11. Leone, M., Zhai, D., Sarteh, S., Kitada, S., Reed, J.C., Pellecchia, M. Cancer prevention by tea polyphenols is linked to their direct inhibition of anti-apoptotic Bcl-2 family proteins. Cancer Res 2003, 63: 8118-21.
12. Oltersdorf, T., Elmore, S.W., Shoemaker, A.R. et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435: 677-81.
13. Pellecchia, M., Reed, J.C. Inhibition of anti-apoptotic Bcl-2 family proteins by natural polyphenols: New avenues for cancer chemoprevention and chemotherapy. Curr Pharm Des 2004, 10: 1387-98.
14. Rudin, C.M., Hann, C.L. Bcl-2 as a therapeutic target in small cell lung cancer. 4th Int Chicago Symp Malig Chest Head Neck (Oct 25-28, Chicago) 2006, Abst 2.06.06.
15. Campàs, C., Cosialls, A.M., Barragán, M. et al. Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells. Exp Hematol 2006, 34(12): 1663-9.
16. Stewart, A.K., Li, Z.H., Wen, X.Y., Rauw, J., Pathangey, L., Bergsagel, P.L., Trudel, S. Studies of Bcl inhibitor GX15-070 in multiple myeloma demonstrate substantial pre-clinical activity. Blood [47th Annu Meet Am Soc Hematol (Dec 10-13, Atlanta) 2005] 2005, 106(11): Abst 1572.
17. Contractor, R., Konopleva, M., Samudio, I., Kantarjian, H., Andreeff, M. Inhibition of Bcl-2 signaling by small molecule BH3 inhibitor GX15-070 as a novel therapeutic strategy in AML. Blood [47th Annu Meet Am Soc Hematol (Dec 10-13, Atlanta) 2005] 2005, 106(11): Abst 3372.
18. Watt, J.C., Konopleva, M., Contractor, R. et al. Inhibition of Bcl-2 signaling by small molecule BH3 inhibitor GX15-070 as a novel therapeutic strategy in AML. Blood [48th Annu Meet Am Soc Hematol (Dec 9-12, Orlando) 2006] 2006, 108(11): Abst 2584.
19. Olney, H.J., Weng, X., Watson, M., Beauparlant, P., Soulières, D., Viallet, J., Sarfati, M. Preclinical evaluation of apoptosis induction by the novel small molecule Bcl-2 inhibitor, GX015-070, in ex vivo chronic lymphoid leukemia (CLL) cells. 41st Annu Meet Am Soc Clin Oncol (ASCO) (May 13-17, Orlando) 2005, Abst 3149.
20. Campas, C., Domingo, A., Gil, J. Pan-Bcl-2 inhibitors induce apoptosis in B-cell chronic lymphocytic leukemia cells. 15th AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 17-21, Boston) 2003, Abst B116.
21. Bronk, S.F., Kaufmann, S.H., Gores, G. GX15-070 sensitizes cholangiocarcinoma cells to TRAIL induced apoptosis by releasing BAK from Mcl-1. 57th Annu Meet Am Assoc Study Liver Dis (Oct 27-31, Boston) 2006, Abst 125.
22. Gomez-Bougie, P., Maiga, S., Pellat-Decaunynck, C., Jouan, S., Bataille, R., Amiot, M. The pan-Bcl-2 inhibitor GX15-070 induces apoptosis in human myeloma cells by Noxa induction and strongly enhances melphalan, bortezomib or TRAIL-R1 antibody apoptotic effect. Blood [48th Annu Meet Am Soc Hematol (Dec 9-12, Orlando) 2006] 2006, 108(11): Abst 3476.
23. Perez-Galan, P., Roue, G., Villamor, N., Campo, E., Colomer, D. The small molecule pan-Bcl-2 inhibitor GX15-070 induces apoptosis in vitro in mantle lymphoma (MCL) cells and exhibits a synergistic effect in combination with the proteasome inhibitor bortezomib. Blood [47th Annu Meet Am Soc Hematol (Dec 10-13, Atlanta) 2005] 2005, 106(11): Abst 1490.
24. Perez-Galan, P., Roue, G., Villamor, N., Campo, E., Colomer, D. The small molecule pan-Bcl-2 inhibitor GX15-070 induces apoptosis in vitro in mantle cell lymphoma (MCL) cells and exhibits a synergistic effect in combination with the proteasome inhibitor bortezomib. Proc Am Assoc Cancer Res (AACR) 2006, 47: Abst 2427.
25. Bebb, G., Muzik, H., Nguyen, S., Morris, D., Stewart, DA. In vitro and in vivo antilymphoma effect of GX15-070 in mantle cell lymphoma. Blood [48th Annu Meet Am Soc Hematol (Dec 9-12, Orlando) 2006] 2006, 108(11): Abst 4756.
26. Yazbeck, V.Y., Georgakis, G.V., Li, Y., McConkey, D., Andreeff, M.,Younes, A. Inhibition of the pan-Bcl-2 family by the small molecule GX15-070 induces apoptosis in mantle cell lymphoma (MCL) cells and enchances the activity of two proteasome inhibitors (NPI-0052 and bortezomib), and doxorubicin chemotherapy. Blood [48th Annu Meet Am Soc Hematol (Dec 9-12, Orlando) 2006] 2006, 108(11): Abst 2532.
27. Shora, G., Watson, M., Roulston, A. et al. Obatoclax (GX15-070) is a potent antagonist of constitutive Mcl-1/Bak interactions in intact mitochondrial membrane and synergizes with bortezomib in mantle cell lymphoma. Blood [48th Annu Meet Am Soc Hematol (Dec 9-12, Orlando) 2006] 2006, 108(11): Abst 832.
28. Rege, J.M., Robinson, B.W., Gupta, M. et al. Pan-BCL-2 family small molecule inhibitor GX015-070 (Gemin X, Inc.) exhibits single agent cytotoxicity, is synergistic with select anti-leukemia cytotoxic agents, and induces apoptosis in cell lines with t(4;11)(q21;q23) translocations. Blood [47th Annu Meet Am Soc Hematol (Dec 10-13, Atlanta) 2005] 2005, 106(11): Abst 3368.
29. Hernandez-Ilizaliturri, J.F., Bhat, S., Iqbal, A., Olejniczak, S., Knight, J., Czuczman, M.S. Targeting BH3-domain anti-apoptotic proteins with GX15-070 significantly increases rituximab-mediated antibody dependent cellular cytotoxicity (ADCC) and complement mediated cytotoxicity (CMC) against B-cell lymphomas. Blood [48th Annu Meet Am Soc Hematol (Dec 9-12, Orlando) 2006] 2006, 108(11): Abst 2502.
30. Hernandez-Ilizaliturri, J.F., Iqbal, A., Alam, N., Bhat, S., Olejniczak, S., Knight, J., Czuczman, M.S. Targeting BH3-domain anti-apoptotic proteins with GX15-070 decreases DNA synthesis, induces cell death and sensitizes rituximab-sensitive and resistant non-Hodgkin's lymphoma cell lines to the antitumor activity of chemotherapy agents. Blood [48th Annu Meet Am Soc Hematol (Dec 9-12, Orlando) 2006] 2006, 108(1): Abst 2523.
31. Witters, L., Witkoski, A., Planas-Silva, M., Viallet, J., Berger, M., Lipton, A. Synergistic inhibition of breast cancer cell lines with the combination of a dual inhibitor of EGFR/HER-2/neu and a Bcl-2 inhibitor. 42nd Annu Meet Am Soc Clin Oncol (ASCO) (June 3-8, Atlanta) 2006, Abst 13100.
32. Witters, L.M., Witkoski, A., Planas-Silva, M.D., Berger, M., Viallet, J., Lipton, A. Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor. Oncol Rep 2007, 17(2): 465-9.
33. Haura, E., Li, J., Viallet, J. GX15-070, a small molecule Bcl-2 family inhibitor, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells. Eur J Cancer-Suppl [18th EORTC-NCI-AACR Symp Mol Targets Cancer Ther (Nov 7-10, Prague) 2006] 2006, 4(12): Abst 613.
34. Bebb, D., Muzik, H., Ding, Y. Susceptibility of mantle cell lymphoma (MCL) and non-small cell lung cancer cell lines to targeting Bcl-2 using the small molecular inhibitor, GX15-070. 4th Int Symp Target Anticancer Ther (March 16-18, Amsterdam) 2006, Abst P. 201.
35. McGreivy, J.S., Marshall, J., Cheson, B.D. et al. Initial results from ongoing phase I trials of a novel pan bcl-2 family small molecule inhibitor. 41st Annu Meet Am Soc Clin Oncol (ASCO) (May 13-17, Orlando) 2005, Abst 3180.
36. Firozvi, K., Hwang, J., Hansen, N. et al. A phase I study of the pan-Bcl2 family inhibitor GX15-070, administered as a 3-hour weekly infusion in patients with refractory solid tumors or lymphomas. 42nd Annu Meet Am Soc Clin Oncol (ASCO) (June 3-6, Atlanta) 2006, Abst 3081.
37. Borthakur, G., O'Brien, S., Ravandi-Kashani, F., Giles, F., Schimmer, A.D.,Viallet, J., Kantarjian, H. A phase I trial of the small molecule pan-Bcl-2 family inhibitor obatoclax mesylate (GX15-070) administered by 24 hour infusion every 2 weeks to patients with myeloid malignancies and chronic lymphocytic leukemia (CLL). Blood [48th Annu Meet Am Soc Hematol (Dec 9-12, Orlando) 2006] 2006; 108(11): Abst 2654.
38. O'Brien, S., Kipps, T.J., Faderl, S. et al. A phase I trial of the small molecule pan-Bcl-2 family inhibitor GX15-070 administered intravenously (IV) every 3 weeks to patients with previously treated chronic lymphocytic leukemia (CLL). Blood [47th Annu Meet Am Soc Hematol (Dec 10-13, Atlanta) 2005] 2005, 106(11): Abst 446.
39. GX15-070 enters phase I/II trial in CLL, receives orphan drug status. DailyDrugNews.com, January 13, 2005.
40. GX15-070 begins new trials in NSCLC and mantle cell lymphoma. DailyDrugNews.com, February 2, 2007.
41. Safety and efficacy of obatoclax mesylate (GX15-070MS) for the treatment of myelodysplastic syndromes (MDS) (NCT00413114). ClinicalTrials.gov Web site, March 15, 2007.
42. Safety and efficacy of single agent obatoclax mesylate (GX15-070MS) followed by a combination with rituximab for previously-untreated follicular lymphoma (FL) (NCT00427856). ClinicalTrials.gov Web site, March 15, 2007.
43. Safety and efficacy of obatoclax mesylate (GX15-070MS) in combination with bortezomib for the treatment of relapsed or refractory mantle cell lymphoma (MCL) (NCT00407303). ClinicalTrials.gov Web site, March 15, 2007.
44. Safety and efficacy of obatoclax mesylate (GX15-070MS) in combination with docetaxel for the treatment of non-small cell lung cancer (NCT00405951). ClinicalTrials.gov Web site, March 15, 2007.
45. Safety and efficacy of obatoclax mesylate (GX15-070MS) in the treatment of myelofibrosis with myeloid metaplasia (NCT00360035). ClinicalTrials.gov Web site, March 15, 2007.
46. Safety and efficacy of obatoclax mesylate (GX15-070MS) in the treatment of Hodgkin's lymphoma (NCT00359892). ClinicalTrials.gov Web site, March 15, 2007.